Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Raptor siRNA is a small interfering RNA (siRNA) designed to specifically knock down the expression of regulatory-associated protein of mTOR (Raptor), a key scaffolding component of the mammalian target of rapamycin complex 1 (mTORC1). By targeting Raptor mRNA for degradation, Raptor siRNA selectively inhibits mTORC1 signaling without directly affecting mTORC2. It is widely used as a research-use-only (RUO) reagent in laboratory settings to study the role of the mTORC1 pathway in cellular processes such as cell growth, proliferation, autophagy, and survival, as well as its involvement in diseases like cancer and intervertebral disc degeneration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Raptor siRNA.